Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer.

IF 5.3 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Marshall D Behrens, Robert J Stiles, Gennett M Pike, Laura A Sikkink, Yongxian Zhuang, Jia Yu, Liewei Wang, Judy C Boughey, Matthew P Goetz, Mark J Federspiel
{"title":"Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer.","authors":"Marshall D Behrens,&nbsp;Robert J Stiles,&nbsp;Gennett M Pike,&nbsp;Laura A Sikkink,&nbsp;Yongxian Zhuang,&nbsp;Jia Yu,&nbsp;Liewei Wang,&nbsp;Judy C Boughey,&nbsp;Matthew P Goetz,&nbsp;Mark J Federspiel","doi":"10.1016/j.omto.2022.11.002","DOIUrl":null,"url":null,"abstract":"<p><p>Historically, the clinical utility of oncolytic virotherapy as a treatment for a wide range of cancer types was first demonstrated by three pilot human clinical trials conducted in Japan in the 1970s and 1980s using a wild-type Urabe mumps virus (MuV) clinical isolate. Using a sample of the actual original oncolytic Urabe MuV clinical trial virus stock (MuV-U-Japan) used in these Japanese clinical trials, we found that MuV-U-Japan consisted of a wide variety of very closely related Urabe MuVs that differed by an average of only three amino acids. Two MuV-U-Japan isolates, MuV-UA and MuV-UC, potently killed a panel of established human breast cancer cell lines <i>in vitro</i>, significantly extended survival of nude mice with human triple-negative breast cancer (TNBC) MDA-MB-231 tumor xenografts <i>in vivo</i>, and demonstrated significant killing activity against breast cancer patient-derived xenograft (PDX) cell lines grown as 3D organoids, including PDXs from patients resistant to anthracycline- and taxane-based chemotherapy. We also report success in developing a large-scale MuV-U production and purification process suitable for supporting Investigational New Drug applications for clinical trials. This study demonstrates the suitability of the MuV-UC virus for translation to modern clinical trials for treating patients with TNBC.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"27 ","pages":"239-255"},"PeriodicalIF":5.3000,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/95/main.PMC9703006.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy Oncolytics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omto.2022.11.002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 4

Abstract

Historically, the clinical utility of oncolytic virotherapy as a treatment for a wide range of cancer types was first demonstrated by three pilot human clinical trials conducted in Japan in the 1970s and 1980s using a wild-type Urabe mumps virus (MuV) clinical isolate. Using a sample of the actual original oncolytic Urabe MuV clinical trial virus stock (MuV-U-Japan) used in these Japanese clinical trials, we found that MuV-U-Japan consisted of a wide variety of very closely related Urabe MuVs that differed by an average of only three amino acids. Two MuV-U-Japan isolates, MuV-UA and MuV-UC, potently killed a panel of established human breast cancer cell lines in vitro, significantly extended survival of nude mice with human triple-negative breast cancer (TNBC) MDA-MB-231 tumor xenografts in vivo, and demonstrated significant killing activity against breast cancer patient-derived xenograft (PDX) cell lines grown as 3D organoids, including PDXs from patients resistant to anthracycline- and taxane-based chemotherapy. We also report success in developing a large-scale MuV-U production and purification process suitable for supporting Investigational New Drug applications for clinical trials. This study demonstrates the suitability of the MuV-UC virus for translation to modern clinical trials for treating patients with TNBC.

Abstract Image

Abstract Image

Abstract Image

溶瘤性乌拉伯腮腺炎病毒:一种有前途的三阴性乳腺癌病毒疗法。
从历史上看,溶瘤病毒疗法作为一种治疗多种癌症类型的临床应用,最早是在20世纪70年代和80年代在日本使用野型Urabe腮腺炎病毒(MuV)临床分离物进行的三次试点人体临床试验中得到证实的。使用这些日本临床试验中使用的实际原始溶瘤性Urabe MuV临床试验病毒库存(MuV- u - japan)的样本,我们发现MuV- u - japan由各种非常密切相关的Urabe MuV组成,平均只有三个氨基酸不同。两株MuV-U-Japan分离株MuV-UA和MuV-UC在体外有效地杀死了一组已建立的人乳腺癌细胞系,在体内显著延长了人三阴性乳腺癌(TNBC) MDA-MB-231肿瘤异种移植物裸鼠的存活时间,并对生长为3D类器官的乳腺癌患者来源的异种移植物(PDX)细胞系显示出显著的杀伤活性,包括对蒽环类和紫杉烷类化疗耐药的患者的PDX。我们还成功开发了大规模的MuV-U生产和纯化工艺,适用于支持临床试验新药申请。这项研究证明了MuV-UC病毒用于治疗TNBC患者的现代临床试验的适用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics Medicine-Oncology
CiteScore
10.90
自引率
3.50%
发文量
152
审稿时长
6 weeks
期刊介绍: Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信